false 0001314052 0001314052 2024-07-24 2024-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2024

 

ANAVEX LIFE SCIENCES CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-37606  98-0608404 
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

630 5th Avenue, 20th Floor, New York, NY USA 10111
(Address of principal executive offices) (Zip Code)

 

1-844-689-3939

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.001 per share   AVXL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

 

Anavex Life Sciences Corp. (the “Company”) was party to a Controlled Equity OfferingSM Sales Agreement, as amended and restated by the Amended and Restated Sales Agreement dated May 1, 2020 (the “A&R Sales Agreement”) with Cantor Fitzgerald & Co. and SVB Securities LLC (the “Sales Agents”), with respect to an ”at-the-market” offering program under which the Company could offer and sell, from time to time at the Company’s sole discretion, shares of its common stock, par value $0.001 per share, through the Sales Agents. On July 24, 2024, the Company terminated the A&R Sales Agreement. There are no penalties associated with the termination of the A&R Sales Agreement.

 

A copy of the A&R Sales Agreement was filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 1, 2020 (the “2020 Form 8-K”).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANAVEX LIFE SCIENCES CORP.
   
  /s/ Christopher Missling
  Name: Christopher Missling, PhD
  Title: Chief Executive Officer
   
Date: July 30, 2024  

 

 

v3.24.2
Cover
Jul. 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 24, 2024
Entity File Number 001-37606
Entity Registrant Name ANAVEX LIFE SCIENCES CORP.
Entity Central Index Key 0001314052
Entity Tax Identification Number 98-0608404
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 630 5th Avenue
Entity Address, Address Line Two 20th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10111
City Area Code 844
Local Phone Number 689-3939
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol AVXL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Anavex Life Sciences (NASDAQ:AVXL)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Anavex Life Sciences